Slaughter and May advised GlaxoSmithKline plc on the sale of remaining stake in Aspen Pharmacare Holdings Ltd

Slaughter and May advised GlaxoSmithKline plc (“GSK”) on the sale of its remaining 6.2% stake in Aspen Pharmacare Holdings Ltd which was announced on 28 September 2016. The disposal was effected by way of an accelerated bookbuilt offering and raised gross proceeds equivalent to £477 million.

GSK’s internal legal team was led by Antony Braithwaite and we worked as an integrated team with Cleary Gottlieb Steen & Hamilton LLP advising on US law and Bowman Gilfillan Inc. advising on South African law.

Cleary Gottlieb Steen & Hamilton: Sebastian R. Sperber (partner), Laura K. Palmer (associate)

Bowman Gilfillan: Ezra Davids (partner), Ryan Wessels (partner)